Klaudia Nowak

Ms. Klaudia Nowak

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in Archives of Virology
Verified
Journal Article
Open access
PDF file
KŁKrzysztof Łupina
Krzysztof Łupina
KNKlaudia Nowak
Klaudia Nowak
DLDominika Lorek
Dominika Lorek
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
ARAnna Romac
Anna Romac
JJJakub Janczura
Jakub Janczura
Human immunodeficiency virus (HIV) remains a global public health challenge, affecting millions worldwide despite significant advancements in antiretroviral therapy (ART). While ART has transformed HIV into a manageable chronic condition, long-term adherence, drug resistance, and access disparities continue to hinder treatment success. Recent research has focused on developing alternative therapeutic strategies, particularly long-acting injectable (LAI) therapies and immunotherapeutic approaches to improve adherence and potentially achieve viral remission. This review explores the evolution of pharmacological advancements in HIV treatment, highlighting the transition from daily oral ART to long-acting formulations such as cabotegravir, rilpivirine, and lenacapavir. LAI therapies reduce the burden of daily adherence, enhance treatment efficacy, and decrease stigma, particularly in vulnerable populations. Additionally, novel immunotherapeutic strategies such as broadly neutralizing antibodies, immune checkpoint inhibitors, and chimeric antigen receptor T cell therapy are being investigated for their potential to induce long-term viral suppression or cure. Despite these promising developments, several challenges remain, including resistance-associated mutations, accessibility issues, and long-term safety concerns. This review summarizes recent clinical trials, discusses the benefits and limitations of emerging HIV therapies, and outlines future research directions. The continued advancement of LAI therapies and immunotherapeutics holds great potential to improve treatment outcomes, expand global access to care, and move closer to a functional cure for HIV.

14 October 2025 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Open access
PDF file
KNKlaudia Nowak
Klaudia Nowak
MPMaria Paluch
Maria Paluch
MCMaja Cudzik
Maja Cudzik
KSKlaudia Syska
Klaudia Syska
WGWiktoria Gawlikowska
Wiktoria Gawlikowska
JJJakub Janczura
Jakub Janczura
Metabolic dysfunction-associated steatotic liver disease (MASLD), the most common subtype of steatotic liver disease (SLD), affects approximately 38% of the global adult population and is strongly linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Projections estimate its prevalence may exceed 55% by 2040. Obesity plays a central role in the progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Excess adiposity contributes to hepatic fat accumulation, systemic inflammation, insulin resistance, and activation of hepatic stellate cells. key mechanisms in liver injury and fibrogenesis. Diagnosis traditionally relied on liver biopsy, but noninvasive techniques, along with serum-based indices, are now commonly used. MASLD is associated with an increased risk of cardiovascular disease, chronic kidney disease, and endocrine disorders, particularly in obese individuals. Management is centered on weight reduction, which can reverse steatosis, resolve MASH, and regress fibrosis depending on the degree of weight loss. Recent therapeutic advances include the approval of resmetirom, a thyroid hormone receptor-β agonist, and promising results from glucagon-like peptide 1 (GLP-1) receptor agonists. Bariatric surgery offers significant benefits in selected patients, improving liver histology and associated metabolic parameters. Despite these developments, no universally accepted pharmacotherapy exists for MASLD. Future directions include expanding access to diagnostic tools, validating novel biomarkers, and implementing public health strategies targeting obesity to prevent progression to end-stage liver disease.

12 March 2025 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
KNKlaudia Nowak
Klaudia Nowak
KŁKrzysztof Łupina
Krzysztof Łupina
ARAnna Romac
Anna Romac
AKAleksandra Kalisz
Aleksandra Kalisz
ŁIŁucja Ilkiewicz
Łucja Ilkiewicz
JJJakub Janczura
Jakub Janczura
Objective: To summarize the current knowledge on the therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using the search terms GLP-1 agonists , MASLD , NAFLD , nonalcoholic fatty liver disease , treatment , and therapy on PubMed (from January 1, 2019, through February 1, 2025), National Institutes of Health (NIH) (from January 1, 2019, through February 1, 2025), Scopus (from January 1, 2019, through February 1, 2025), and the World Health Organization (WHO) data. Study Selection and Data Extraction: All relevant clinical trials, review articles, package inserts, and guidelines evaluating clinically relevant evidence regarding the therapeutic potential of GLP-1 agonists in MASLD were considered for inclusion. Data Synthesis: GLP-1 RAs have shown promising results in MASLD treatment. Semaglutide has demonstrated efficacy in reducing liver fat content, inflammation, and fibrosis, with clinical trials indicating improvements in hepatic biomarkers and cardiometabolic risk factors. Similarly, tirzepatide has been associated with substantial weight loss and significant reductions in liver fat and fibrosis markers. Both agents exert their effects through mechanisms involving improved insulin sensitivity, reduced lipid accumulation, and attenuation of hepatic inflammation. Relevance to Patient Care and Clinical Practice: Given the high prevalence of MASLD in patients with obesity and type 2 diabetes, tirzepatide and semaglutide could play a critical role in clinical practice by addressing multiple facets of the disease. Both agents have shown potential in reducing liver fat, improving hepatic biomarkers, and mitigating cardiometabolic risks, which are leading causes of morbidity and mortality in MASLD patients. Incorporating these therapies into MASLD treatment guidelines could significantly enhance patient outcomes by targeting both liver-related and systemic complications of the disease. Conclusions: GLP1 RAs show great potential in managing MASLD by promoting weight loss, improving glycemic control, and reducing liver inflammation.

20 November 2025 in Korean Journal of Family Medicine
Verified
Journal Article
Open access
PDF file
KNKlaudia Nowak
Klaudia Nowak
ANAdrian Tomasz Nowak
Adrian Tomasz Nowak
AJAleksandra Jabłońska
Aleksandra Jabłońska
APAnna Potaczek
Anna Potaczek
JSJulia Salacha
Julia Salacha
JJJakub Janczura
Jakub Janczura
The global increase in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects more than one-third of the general population and up to 70% of individuals with type 2 diabetes or obesity, is a critical public health challenge. Given that liver steatosis is often asymptomatic until the advanced stages of disease, early detection is essential to prevent its progression to fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma. However, liver biopsy, the gold-standard diagnostic method, is invasive, costly, and unsuitable for large-scale screening. As a result, noninvasive tests have emerged as practical alternatives, particularly in primary care settings, where early identification is most feasible. The present study explored current perspectives of noninvasive liver disease screening tools and their implementation in primary care. Serum-based indices, along with imaging techniques, have demonstrated promise in identifying patients with advanced fibrosis. Novel biomarkers, including the enhanced liver fibrosis test and Pro-C3, as well as emerging artificial intelligence-assisted diagnostic platforms, yield improved accuracy and risk stratification potential. Despite accumulating evidence supporting the clinical utility and cost-effectiveness of noninvasive tests, several barriers hinder their routine use in primary care settings, which include limited funding, lack of standardized guidelines, insufficient clinician training, and disparities in access to diagnostic tools. The implementation of structured stepwise screening models has demonstrated improved diagnostic efficiency and reduced unnecessary referrals. Future research should emphasize the integration of artificial intelligence, portable diagnostic devices, and personalized risk models to enhance early detection. Ensuring widespread adoption requires coordinated efforts in policy development, provider education, and health-system investment. Noninvasive screening tools offer a feasible and cost-effective pathway for the early detection of MASLD in primary care; however, their successful implementation depends on addressing logistical, educational, and systemic barriers.

17 March 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
PSPiotr Starnawski
Piotr Starnawski
KNKlaudia Nowak
Klaudia Nowak
ZAZuzanna Augustyn
Zuzanna Augustyn
DMDominik Malicki
Dominik Malicki
APAleksandra Piąta
Aleksandra Piąta
JJJakub Janczura
Jakub Janczura

12 November 2025 in Healthcare
Verified
Journal Article
Open access
PDF file
KNKlaudia Nowak
Klaudia Nowak
Artur DziewierzArtur Dziewierz
Artur Dziewierz
ASAleksandra Sojda
Aleksandra Sojda
MZMichał Zabojszcz
Michał Zabojszcz
Lukasz SzarpakLukasz Szarpak
Lukasz Szarpak
Zbigniew SiudakZbigniew Siudak
Zbigniew Siudak
Background: Since the introduction of the first GLP-1 receptor agonist (GLP-1 RA) in 2005, there has been a steady increase in the number of drugs available in this group, as well as an expansion of their indications and routes of administration. Aim: The aim of the study was to assess the clinical characteristics of patients treated with GLP-1 RA in Poland in 2018–2024, with particular emphasis on the disease entities constituting indications for treatment (like obesity and diabetes), and to analyse the frequency of use of individual drugs during the study period. Methods: A cohort study was conducted based on anonymised medical data from 300 outpatient clinics the largest private healthcare facilities in Poland (Luxmed), on consecutive patients who had at least one prescription for GLP-1 RA. The analysis covered the period from 1 January 2018 to 31 December 2024. Results: The number of patients using GLP-1 RA increased from 212 in 2018 to 12,836 in 2024. Obesity was diagnosed in 78% of all patients, most often in the groups using liraglutide and tirzepatide. The highest percentage of patients with type 2 diabetes was observed in the dulaglutide group (67%), while the lowest was in the tirzepatide group (15%). From 2022, the share of oral semaglutide steadily increased, reaching 50% of all semaglutide applications in 2024 in Poland. Conclusions: In the analysed group, GLP-1 RAs were most commonly used to treat obesity. The oral form of semaglutide was more frequently used in younger females with less aggravating medical history.